{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:49:57Z","timestamp":1757616597957,"version":"3.44.0"},"reference-count":50,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Fam Plann Reprod Health Care"],"accepted":{"date-parts":[[2004,5,28]]},"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Several areas exist in the practice of contraception where evidence for practice is deficient, yet clinical decisions need to be made.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of the study was to find the practice habits of lead practitioners in the area of contraception in specific clinical scenarios where the published evidence is inadequate to provide clear guidance to clinicians. Results can provide \u2018Level V\u2019 evidence for practice for the \u2018nonexpert\u2019 practitioner.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Descriptive study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>The study was conducted as a postal questionnaire mailed to the 205 lead practitioners whose contact details were known through the Society of Consultants in Reproductive Health (hereafter referred to as 'consultants') working in reproductive health in the National Health Service.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 138 consultants returned completed questionnaires (67% response rate). Important results included 100% of respondents being prepared to prescribe progestogen-only emergency contraception more than once in a cycle (contrary to product labelling) and 71% recommending two tablets daily of the progestogen-only pill for women of high body mass.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Some questions had responses that showed clear majorities, providing a clear guide to practice, while other areas remain doubtful. Comments from respondents indicated great interest in all areas covered and a desire for consensus on many of the issues. Certainly the licensing and the advice from pharmaceutical companies is conservative, and in many scenarios a majority of consultants indicated that in order to serve the best interests of their clients they feel constrained to practise outside the Summary of Product Characteristics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1783\/0000000042177063","type":"journal-article","created":{"date-parts":[[2005,3,5]],"date-time":"2005-03-05T01:30:57Z","timestamp":1109986257000},"page":"229-236","source":"Crossref","is-referenced-by-count":2,"title":["Unanswered questions in contraceptive management: What do the experts do?"],"prefix":"10.1136","volume":"30","author":[{"given":"Catherine","family":"Brooker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Guillebaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2004,10,1]]},"reference":[{"key":"ref_1","article-title":"Contraception \u2013 Your Questions Answered (3rd","author":"A, Guillebaud J.Appendix","year":"2004","unstructured":"Guillebaud J. Appendix A. Contraception \u2013 Your Questions Answered (3rd, 4th edns). Edinburgh, UK: Churchill Livingstone, 1999, 2004.","edition":"4th edns"},{"key":"ref_2","article-title":"Contraception Today","author":"Guillebaud, J.","year":"2004","unstructured":"Guillebaud J. Contraception Today (5th edn). London, UK: Martin Dunitz, 2004.","edition":"5th edn"},{"key":"ref_3","article-title":"Levels of Evidence and Grades of Recommendations. Oxford Centre for Evidence-based Medicine Levels of Evidence","author":"Phillips, B.; Ball, C.; Sackett, D.","year":"2001","unstructured":"Phillips B, Ball C, Sackett D, et al. Levels of Evidence and Grades of Recommendations. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). http:\/\/www.cebm.net\/levels _of_evidence.asp. November 1998."},{"author":"[April 2004].","unstructured":"UK Data Sheet Compendium. http:\/\/www.emc.medicines.org.uk [Accessed April 2004].","article-title":"UK Data Sheet Compendium","key":"ref_4"},{"key":"ref_5","first-page":"79","article-title":"Effectiveness of progestogen-only oral contraceptives","volume":"16","author":"Vessey, M.P.; Villard-Mackintosh, L.; Yeates, D.","year":"1990","unstructured":"Vessey MP, Villard-Mackintosh L, Yeates D. Effectiveness of progestogen-only oral contraceptives. Br J Fam Plann 1990; 16: 79.","journal-title":"Br J Fam Plann"},{"key":"ref_6","first-page":"165","article-title":"A pre-coital pill? A preliminary in vitro study","volume":"26","author":"Kovacs, G.; Hendricks, J.; Summerbell, D.","year":"2000","unstructured":"Kovacs G, Hendricks J, Summerbell D, et al. A pre-coital pill? A preliminary in vitro study. Br J Fam Plann 2000; 26: 165\u2013166.","journal-title":"Br J Fam Plann"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1783\/147118901101195713","article-title":"Progestogen-only pills (POPs) and body weight","volume":"27","author":"Guillebaud, J.","year":"2001","unstructured":"Guillebaud J. Progestogen-only pills (POPs) and body weight. J Fam Plann Reprod Health Care 2001; 27: 239.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_8","article-title":"Contraception and Office Gynaecology","author":"Kubba, A.; Sanfilippo, J.; Hampton, N.","year":"1999","unstructured":"Kubba A, Sanfilippo J, Hampton N. Contraception and Office Gynaecology. London, UK: W B Saunders, 1999."},{"year":"1998","author":"Hatcher, R.A.; Trussell, J.; Stewart, F.","unstructured":"Hatcher RA, Trussell J, Stewart F, et al. (eds). Contraceptive Technology. New York, NY: Ardent Media Inc., 1998.","key":"ref_9"},{"key":"ref_10","article-title":"Handbook of Family Planning and Reproductive Health Care","author":"Glasier, A.; Gebbie, A.","year":"2000","unstructured":"Glasier A, Gebbie A. Handbook of Family Planning and Reproductive Health Care (4th edn). London, UK: Churchill Livingstone, 2000.","edition":"4th edn"},{"issue":"3","key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1783\/147118903101197584","article-title":"The members\u2019 enquiry service: frequently asked questions","volume":"29","author":"de Souza A; S, Brechin; G, Penney","year":"2003","unstructured":"de Souza A, Brechin S, Penney G. The members\u2019 enquiry service: frequently asked questions. J Fam Plann Reprod Health Care 2003; 29(3): 160\u2013161.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"3","key":"ref_12","first-page":"162","article-title":"Desogestrel-only pill (Cerazette)","volume":"29","author":"Brechin, S.; Penney, G.; de Souza, A.","year":"2003","unstructured":"Brechin S, Penney G, de Souza A. New Product Review (April 2003). Desogestrel-only pill (Cerazette). J Fam Plann Reprod Health Care 2003; 29(3): 162\u2013164.","journal-title":"New Product Review"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM199710093371507","article-title":"Emergency postcoital contraception","volume":"337","author":"Glasier, A.","year":"1997","unstructured":"Glasier A. Emergency postcoital contraception. N Engl J Med 1997; 337: 1058\u20131064.","journal-title":"N Engl J Med"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(98)05145-9","article-title":"Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception","volume":"352","year":"1998","unstructured":"Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428\u2013433.","journal-title":"Lancet"},{"year":"2003","unstructured":"Schering website. http:\/\/www.schering.co.uk\/content\/health_pros (updated November 2003).","article-title":"Schering website","key":"ref_15"},{"issue":"2","key":"ref_16","first-page":"9","article-title":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance. Emergency contraception","volume":"29","year":"2003","unstructured":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance. Emergency contraception. J Fam Plann Reprod Health Care 2003; 29(2): 9\u201316.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(02)11767-3","article-title":"Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial","volume":"360","author":"von Hertzen H; G, Piaggio; J, Ding","year":"2002","unstructured":"von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803\u20131810.","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/bmj.321.7271.1259","article-title":"The timing of the \u201cfertile window\u201d in the menstrual cycle: day specific estimate from a prospective study","volume":"321","author":"Wilcox, A.J.; Dunson, D.; Baird, D.","year":"2000","unstructured":"Wilcox AJ, Dunson D, Baird D. The timing of the \u201cfertile window\u201d in the menstrual cycle: day specific estimate from a prospective study. BMJ 2000; 321: 1259\u20131262.","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00023210-200216040-00005","article-title":"Interactions between antiepileptic drugs and hormonal contraception","volume":"16","author":"Crawford, P.","year":"2002","unstructured":"Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263\u2013272.","journal-title":"CNS Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1783\/147118902101195992","article-title":"Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs","volume":"28","author":"Bounds, W.; Guillebaud, J.","year":"2002","unstructured":"Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002; 28: 78\u201380.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/bmj.321.7273.1382","article-title":"Drug points: apparent p229-235 - Brooker 9\/14\/04 3: 29 PM Page 7 interaction between warfarin and levonorgestrel used for emergency contraception","volume":"321","author":"Ellison, J.; Thomson, A.J.; Greer, I.A.","year":"2000","unstructured":"Ellison J, Thomson, AJ, Greer IA, et al. Drug points: apparent p229-235 - Brooker 9\/14\/04 3:29 PM Page 7 interaction between warfarin and levonorgestrel used for emergency contraception. BMJ 2000; 321: 1382.","journal-title":"BMJ"},{"key":"ref_22","first-page":"843","article-title":"St John\u2019s Wort: a pharmaceutical with potentially dangerous interactions","volume":"90","author":"Ratz, A.E.; von Moos, M.; Drewe, J.","year":"2001","unstructured":"Ratz AE, von Moos M, Drewe J. St John\u2019s Wort: a pharmaceutical with potentially dangerous interactions. Schweiz Rundsch Med Prax 2001; 90: 843\u2013849.","journal-title":"Schweiz Rundsch Med Prax"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0015-0282(01)02846-1","article-title":"A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy","volume":"76","author":"Varila, E.; Wahlstrom, T.; Rauramo, I.","year":"2001","unstructured":"Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969\u2013975.","journal-title":"Fertil Steril"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00006254-200202000-00024","article-title":"Non-contraceptive health benefits of intrauterine devices: a systematic review","volume":"57","author":"Hubacher, D.; Grimes, D.A.","year":"2002","unstructured":"Hubacher D, Grimes DA. Non-contraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynaecol Surv 2002; 57: 120\u2013128.","journal-title":"Obstet Gynaecol Surv"},{"key":"ref_25","first-page":"1322","article-title":"Long term use of copper intrauterine devices. A statement from the Medical Advisory Committee of the Family Planning","volume":"335","author":"Newton, J.; Tacchi, D.","year":"1990","unstructured":"Newton J, Tacchi D. Long term use of copper intrauterine devices. A statement from the Medical Advisory Committee of the Family Planning Association and the National Association of Family Planning Doctors. Lancet 1990; 335: 1322\u20131323.","journal-title":"Association and the National Association of Family Planning Doctors. Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0010-7824(90)90046-X","article-title":"Long term contraception with levonorgestrel 20mcg\/day (Lng 20) and CopperT 380Ag intrauterine devices: a 5 year randomized study","volume":"42","author":"Sivin, S.; el Mahgoub, S.; McCarthy, T.","year":"1990","unstructured":"Sivin S, el Mahgoub S, McCarthy T, et al. Long term contraception with levonorgestrel 20mcg\/day (Lng 20) and CopperT 380Ag intrauterine devices: a 5 year randomized study. Contraception 1990; 42: 361\u2013378.","journal-title":"Contraception"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0010-7824(91)90149-A","article-title":"Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20mcg\/day (Lng 20) and CopperT 380Ag IUDS","volume":"44","author":"Sivin, I.; Stern, J.; Coutinho, E.","year":"1991","unstructured":"Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20mcg\/day (Lng 20) and CopperT 380Ag IUDS. Contraception 1991; 44: 473\u2013480.","journal-title":"Contraception"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0010-7824(00)00182-7","article-title":"Menstruation: choosing whether... and when","volume":"62","author":"Kaunitz, A.M.","year":"2000","unstructured":"Kaunitz AM. Menstruation: choosing whether... and when. Contraception 2000; 62: 277\u2013284.","journal-title":"Contraception"},{"issue":"4","key":"ref_29","first-page":"209","article-title":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit","volume":"29","year":"2003","unstructured":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance (October 2003). First prescription of combined oral contraception. J Fam Plann Reprod Health Care 2003; 29(4): 209\u2013223.","journal-title":"First prescription of combined oral contraception; J Fam Plann Reprod Health Care"},{"key":"ref_30","first-page":"\"9","article-title":"Cyproterone acetate (Dianette): risk of venous thromboembolism","volume":"28","author":"Vasilakis-Scaramozza, C.; Jick, H.","year":"2002","unstructured":"Committee for the Safety of Medicines\/Medicines Control Agency (CSM\/MCA). Cyproterone acetate (Dianette): risk of venous thromboembolism. Curr Probl Pharmacovigilance 2002; 28: 9\u201310. http:\/\/www.mca.gov.uk.31 Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358:1427\u20131429.","journal-title":"Curr Probl Pharmacovigilance; Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-199614010-00004","article-title":"Cyproterone acetate: is it hepatoor genotoxic?","volume":"14","author":"Rabe, T.; Feldman, K.; Heinemann, L.","year":"1996","unstructured":"Rabe T, Feldman K, Heinemann L, et al. Cyproterone acetate: is it hepatoor genotoxic? Drug Saf 1996; 14: 25\u201338.","journal-title":"Drug Saf"},{"key":"ref_32","first-page":"275","article-title":"The Collaborative MILTS Project Team. Oral contraceptives and liver cancer \u2013 results of the Multicentre International Liver Tumour Study","volume":"56","year":"1997","unstructured":"The Collaborative MILTS Project Team. Oral contraceptives and liver cancer \u2013 results of the Multicentre International Liver Tumour Study. Contraception 1997; 56: 275\u2013284.","journal-title":"Contraception"},{"issue":"3","key":"ref_33","first-page":"127","article-title":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit","volume":"29","year":"2003","unstructured":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance (July 2003). Contraceptive choices for women with inflammatory bowel disease. J Fam Plann Reprod Health Care 2003; 29(3): 127\u2013135.","journal-title":"Contraceptive choices for women with inflammatory bowel disease; J Fam Plann Reprod Health Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1471-0528.1979.tb10694.x","article-title":"An analysis of the influences of maternal age, gestational age, contraceptive method and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy","volume":"86","author":"Stone, M.; Bagshawe, K.D.","year":"1979","unstructured":"Stone M, Bagshawe KD. An analysis of the influences of maternal age, gestational age, contraceptive method and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J Obstet Gynaecol 1979; 86: 782\u2013792.","journal-title":"Br J Obstet Gynaecol"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S1701-2163(16)30408-X","article-title":"Gestational trophoblastic disease","volume":"24","author":"Gerulath, A.H.; Ehlen, T.G.; Bessetle, P.","year":"2002","unstructured":"Gerulath AH, Ehlen TG, Bessetle P, et al. Gestational trophoblastic disease. J Obstet Gynaecol Can 2002; 24: 434\u2013446.","journal-title":"J Obstet Gynaecol Can"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.310.6983.830","article-title":"Case-control of migraine and risk of ischaemic stroke in young women","volume":"310","author":"Tzourio, C.; Tehindrazanarivelo, A.; Igle\u2019sias, S.","year":"1995","unstructured":"Tzourio C, Tehindrazanarivelo A, Igle\u2019sias S, et al. Case-control of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830\u2013833.","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(96)90669-8","article-title":"History of migraine and risk of cerebral ischaemia in young adults","volume":"347","author":"Carolei, A.; Marini, C.; G, De Matteis; the Italian National Research Study Council Group on Stroke in the Young","year":"1996","unstructured":"Carolei A, Marini C, De Matteis G and the Italian National Research Study Council Group on Stroke in the Young. History of migraine and risk of cerebral ischaemia in young adults. Lancet 1996; 347: 1503\u20131506.","journal-title":"Lancet"},{"issue":"8416","key":"ref_38","article-title":"Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication No","volume":"90","author":"States Public Health Service, Office on Smoking and Health","year":"1990","unstructured":"United States Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication No. (CDC) 90-8416. Rockville, MD: United States Public Health Service, Office on Smoking and Health, 1990.","journal-title":"(CDC)"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-119-10-199311150-00005","article-title":"Smoking cessation in relation to total morbidity rates in women: a prospective cohort study","volume":"119","author":"Kawachi, C.I.; Colditz, G.A.; Stampfer, M.J.","year":"1993","unstructured":"Kawachi CI, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total morbidity rates in women: a prospective cohort study. Ann Intern Med 1993; 119: 992\u20131000.","journal-title":"Ann Intern Med"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and their risk of breast cancer","volume":"346","author":"Marchbanks, P.; McDonald, J.; Wilson, H.","year":"2002","unstructured":"Marchbanks P, McDonald J, Wilson H, et al. Oral contraceptives and their risk of breast cancer. N Engl J Med 2002; 346: 2025\u20132032.","journal-title":"N Engl J Med"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jama.284.14.1791","article-title":"Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer","volume":"284","author":"Grabrick, D.; Hartmann, L.; Cerhan, J.","year":"2000","unstructured":"Grabrick D, Hartmann L, Cerhan J, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284: 1791\u20131798.","journal-title":"JAMA"},{"issue":"4","key":"ref_42","article-title":"A current perspective of genetic testing for breast and ovarian cancer: the oral contraceptive decision (Review)","volume":"3","author":"Friedenson, B.","year":"2001","unstructured":"Friedenson B. A current perspective of genetic testing for breast and ovarian cancer: the oral contraceptive decision (Review). MedGenMed 2001; 3(4). http:\/\/www.medscape.com\/viewarticle\/408191 [Accessed 5 January 2004].","journal-title":"MedGenMed"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers","volume":"94","author":"Narod, S.A.; Dube, M.P.; Klijn, J.","year":"2002","unstructured":"Narod SA, Dube MP, Klijn J. Oral contraceptives and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773\u20131770.","journal-title":"J Natl Cancer Inst"},{"year":"2000","unstructured":"World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use. Geneva, Switzerland: WHO, 2000.","article-title":"World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use","key":"ref_44"},{"year":"2002","unstructured":"World Health Organization (WHO). Selected Practice Recommendations for Contraceptive Use. Geneva, Switzerland: WHO, 2002.","article-title":"World Health Organization (WHO). Selected Practice Recommendations for Contraceptive Use","key":"ref_45"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.contraception.2003.07.007","article-title":"A consensus process to adapt the World Health Organization Selected Practice Recommendations for UK use","volume":"68","author":"Glasier, A.; Brechin, S.; Raine, R.","year":"2000","unstructured":"Glasier A, Brechin S, Raine R, et al. A consensus process to adapt the World Health Organization Selected Practice Recommendations for UK use. Contraception 2000; 68: 327\u2013333.","journal-title":"Contraception"},{"key":"ref_47","first-page":"PM","article-title":"Call us on 0845 300 12 12 or visit www.mariestopes.org.uk p236 - MFFP exams 9\/14\/04 3","year":"31","unstructured":"Call us on 0845 300 12 12 or visit www.mariestopes.org.uk p236 - MFFP exams 9\/14\/04 3:31 PM Page 1"},{"key":"ref_48","article-title":"B) examinations will be held on Tuesday 5 April 2005 (applications must be received by 1 January 2005) and on Friday","author":"and, Part 1 (A","year":"2005","unstructured":"Part 1 (A and B) examinations will be held on Tuesday 5 April 2005 (applications must be received by 1 January 2005) and on Friday 21 October 2005 (applications must be received by 1 July 2005)."},{"key":"ref_49","article-title":"Critical Reading Question examination paper (CRQ) Modified Essay Question examination paper (MEQ) Objective Structured Clinical Examination (OSCE) Applications for the Part 2 held in June 2005 must be received by","volume-title":"Please consult the revised Examination regulations","year":"2004","unstructured":"Critical Reading Question examination paper (CRQ) Modified Essay Question examination paper (MEQ) Objective Structured Clinical Examination (OSCE) Applications for the Part 2 held in June 2005 must be received by 1 December 2004. Please consult the revised Examination regulations (June 2004) for changes to entry requirements."},{"issue":"20 7724","key":"ref_50","first-page":"5333","article-title":"The qualification is subject to re-certification every 5 years. Revised regulations (June 2004), application forms and dissertation documents are available on application to: Miss Denise Newell, Examination Secretary, Faculty of Family Planning and Reproductive Health Care of the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent\u2019s Park, London NW1 4RG, UK","volume":"0","unstructured":"The qualification is subject to re-certification every 5 years. Revised regulations (June 2004), application forms and dissertation documents are available on application to: Miss Denise Newell, Examination Secretary, Faculty of Family Planning and Reproductive Health Care of the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent\u2019s Park, London NW1 4RG, UK. Tel: +44 (0) 20 7724 5629. Fax: +44 (0) 20 7723 5333. E-mail: denise@ffprhc.org.uk. Website: www.ffprhc.org.uk","journal-title":"Tel"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1783\/0000000042177063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:33:23Z","timestamp":1757100803000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1783\/0000000042177063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,10,1]]},"published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1783\/0000000042177063"],"URL":"https:\/\/doi.org\/10.1783\/0000000042177063","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"type":"print","value":"1471-1893"},{"type":"electronic","value":"2045-2098"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}